



## First stereoselective total synthesis of trichoderme A

Palakodety Radha Krishna\*, Raghu Ram Kadiyala

D-211, Discovery Laboratory, Organic Chemistry Division-III, Indian Institute of Chemical Technology, Hyderabad 500 607, India

### ARTICLE INFO

#### Article history:

Received 4 June 2010

Revised 8 July 2010

Accepted 13 July 2010

Available online 16 July 2010

#### Keywords:

Cyclopentenones

Baylis–Hillman reaction

Sharpless kinetic resolution

Sharpless asymmetric epoxidation

Hoveyda–Grubbs catalyst

Ring-closing metathesis

### ABSTRACT

The first stereoselective total synthesis of trichoderme A using Baylis–Hillman and ring-closing metathesis (RCM) reactions as key steps is reported.

© 2010 Elsevier Ltd. All rights reserved.

The genus *Trichoderma* is well known for its bio-control constituents and has been extensively investigated.<sup>1</sup> Trichoderme A (**1**) is a new type of cyclopentenone isolated from the strain *Trichoderma* sp. YLF-3 with antibacterial properties.<sup>2</sup> Trichoderme A attracted our attention as the synthetic target primarily due to its fascinating structural features consisting of a highly substituted cyclopentenone system with two stereogenic centers; one on the ring skeleton and the other one as an appendage at C3 in the form of a '1'S-hydroxy ethyl' moiety. The labile hydroxyl functionality at C4 and a base-sensitive C5-methylene next to the ketone functionality add up to the synthetic difficulty. Herein we report the first stereoselective total synthesis of trichoderme A (**1**) from the commercially available starting material acetaldehyde (**6**) by adopting the synthetic route as depicted in Scheme 1.

For the last few years we have been involved in expanding the horizon of asymmetric Baylis–Hillman reaction<sup>3a</sup> and found varied applications of the corresponding adducts.<sup>3b–d</sup> Furthering their use in natural product chemistry<sup>3b</sup> we identified the optically pure adduct **5** (Scheme 1) that could be realized from the Baylis–Hillman reaction between acetaldehyde (**6**) and ethyl acrylate followed by the Sharpless kinetic resolution as an ideal starting material for the synthesis of **1**. The second stereogenic center was planned through the Sharpless asymmetric epoxidation of the allyl alcohol derived from **5** (vide infra Scheme 2) and the reductive ring-opening reaction of the corresponding epoxide to afford the 1,3-diol **4**. Diol **4** on chain extension first leads to the bis-olefin **3** which on Hoveyda–Grubbs catalyst-assisted RCM results in the cyclopentenol **2** that could be conveniently elaborated to the target compound **1**.


Thus, the synthesis (Scheme 2) of **1** starts from the known<sup>4</sup> acetaldehyde Baylis–Hillman adduct **7**, which on Sharpless kinetic resolution<sup>5</sup> {(–)-DIPT/Ti(O<sup>i</sup>Pr)<sub>4</sub>/CHP/CH<sub>2</sub>Cl<sub>2</sub>/–20 °C/45%} gave the desired chiral BH-adduct **5** as an optically pure *S*-isomer.<sup>4</sup> Hydroxy functionality in adduct **5** was protected as its MOM-ether **8** (MOM-Cl/DIPEA/CH<sub>2</sub>Cl<sub>2</sub>/rt/99%) and the ester functionality was reduced (DIBAL-H/CH<sub>2</sub>Cl<sub>2</sub>/0 °C/3 h/89%) to its corresponding alcohol **9**. Primary alcohol on Swern oxidation followed by Wittig olefination reaction afforded the conjugated ester **10** (96% over two steps), which on reduction with DIBAL-H gave the allylic alcohol **11**. Allylic alcohol **11** was converted to epoxy alcohol **12** using Sharpless epoxidation<sup>6</sup> conditions {(+)-DIPT/Ti(O<sup>i</sup>Pr)<sub>4</sub>/CHP/CH<sub>2</sub>Cl<sub>2</sub>/–20 °C/92%}. Reductive ring-opening reaction of **12** with Red-Al in CH<sub>2</sub>Cl<sub>2</sub> afforded the desired 1,3-diol **4** in good yield. Primary alcohol of diol **4** was protected as its benzoate ester (Bz-Cl/Et<sub>3</sub>N/DMAP/rt/2 h/89%) and the secondary alcohol as its MOM-ether (MOMCl/DIPEA/CH<sub>2</sub>Cl<sub>2</sub>/rt/99%) to furnish the all protected intermediate **13**. Deprotection (K<sub>2</sub>CO<sub>3</sub>/MeOH/rt/1 h/87%) of benzoyl group gave the primary alcohol **14**.

Next, the homologation of compound **14** to the RCM precursor **3** was planned in the following way. Firstly, the alcohol **14** was oxidized under Swern conditions to afford the corresponding aldehyde which was subjected to vinylation reaction (vinyl-MgBr/THF/–20 °C/20 min/83%) without any purification to afford the bis-olefin **3** as a 1:1 diastereomeric mixture. No efforts were made to separate the isomers because the carbon bearing the newly generated hydroxyl group later transforms into a ketone functionality.


Subsequently, the bis-olefin **3** on Hoveyda–Grubbs catalyst<sup>7</sup> (10 mol %) assisted ring-closing metathesis (RCM) under refluxing conditions in toluene gave the MOM-protected cyclopentenol **2**

\* Corresponding author. Fax: +91 40 27160387.

E-mail address: [prkgenius@iict.res.in](mailto:prkgenius@iict.res.in) (P.R. Krishna).



Scheme 1. Retrosynthetic analysis.



**Scheme 2.** Reagents and conditions: (a) ethyl acrylate, DABCO, DMF 12 h, 85%. (b) (–)-DIPT, Ti(O<sup>i</sup>Pr)<sub>4</sub>, CHP, –20 °C, 4d, 45%. (c) MOM-Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 12 h, 99%. (d) DIBAL-H, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 3 h, 89%. (e) (COCl)<sub>2</sub>, DMSO, CH<sub>2</sub>Cl<sub>2</sub>, –78 °C, 1 h, 98%. (f) PPh<sub>3</sub>=COOMe, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 3 h, 98%. (g) DIBAL-H, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 3 h, 86%. (h) (+)-DIPT, Ti(O<sup>i</sup>Pr)<sub>4</sub>, CHP, –20 °C, 12 h, 92%. (i) Red-Al CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 3 h, 79%. (j) Bz-Cl, Et<sub>3</sub>N, DMAP, 2 h, 89%. (k) MOM-Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 12 h, 99%. (l) K<sub>2</sub>CO<sub>3</sub>, MeOH, 1 h, 87%. (m) (COCl)<sub>2</sub>, DMSO, CH<sub>2</sub>Cl<sub>2</sub>, –78 °C, 1 h, 98%. (n) VinylMgBr, THF, –20 °C, 20 min, 83%. (o) HG-2nd generation catalyst (10 mol %), toluene, reflux, 5 h, 94%. (p) DMP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C. (q) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 98%.

(94%) as an inseparable 1:1 diastereomeric mixture. <sup>1</sup>H NMR spectrum of compound **2** revealed the lone olefinic proton resonating at  $\delta$  5.89 ppm as a doublet ( $J = 11.7$  Hz). The HRMS spectrum displayed the [M+Na]<sup>+</sup> 255.1465, calculated 255.1463 for the molecular formula C<sub>11</sub>H<sub>20</sub>O<sub>5</sub>Na. Cyclopentenol **2** on oxidation<sup>8</sup> (Dess–Martin periodinane/CH<sub>2</sub>Cl<sub>2</sub>/0 °C/93%) gave cyclopentenone **15**. Finally, deprotection of the MOM groups in **15** with TFA gave the trichodermonaldehyde **1**. Compound **1** was characterized by its spectral data and was found consistent with the reported values.<sup>2,9</sup> Thus the <sup>1</sup>H NMR spectrum of **1** revealed the lone olefinic proton resonating at  $\delta$  6.09 ppm as a singlet and one of the allylic protons (H-4) resonating at  $\delta$  5.07 ppm as a broad doublet ( $J = 5.3$  Hz) while

the other one (H-6) resonated at  $\delta$  4.93 ppm as a quartet ( $J = 6.4$  Hz). The protons due to C5-methylene group displayed an AB multiplicity pattern with one of the diastereotopic protons appearing at  $\delta$  2.86 ppm as a doublet of doublet ( $J = 6.4, 18.5$  Hz) and the other one resonated at  $\delta$  2.42 ppm also as a doublet of doublet ( $J = 1.8, 16.7$  Hz). The protons due to the methyl group appeared at  $\delta$  1.53 ppm as a doublet ( $J = 6.7$  Hz). The HRMS spectrum displayed [M+Na]<sup>+</sup> 165.1269, calculated 165.1266 for the molecular formula C<sub>7</sub>H<sub>10</sub>O<sub>3</sub>Na.

In summary, we described the first stereoselective total synthesis of trichodermonaldehyde **1** using Baylis–Hillman reaction and RCM as the key steps.

## Acknowledgment

One of the authors (R.R.K.) thanks CSIR, New Delhi, for financial support in the form of a fellowship.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.tetlet.2010.07.081](https://doi.org/10.1016/j.tetlet.2010.07.081).

## References and notes

- Druzhinina, I.; Kubicek, C. P. *J. Zhejiang Univ. Sci.* **2005**, *6B*, 100–112.
- Li, G.-H.; Zheng, L.-I.; Liu, F.-F.; Dang, L.-Z.; Li, L.; Huang, R.; Zhang, K.-Q. *Nat. Prod. Res.* **2009**, *23*, 1431–1435.
- (a) Radha Krishna, P.; Rachna, S.; Reddy, P. S. *Synlett* **2008**, 2897–2912; (b) Radha Krishna, P.; Narasingam, M.; Kannan, V. *Tetrahedron Lett.* **2004**, *45*, 4773–4775; (c) Radha Krishna, P.; Narasingam, M. *J. Comb. Chem.* **2007**, *9*, 62–69; (d) Radha Krishna, P.; Reddy, P. S. *J. Comb. Chem.* **2008**, *10*, 426–435.
- Hayashi, N.; Yanagihara, K.; Tsuboi, S. *Tetrahedron: Asymmetry* **1998**, *9*, 3825–3830.
- (a) Martin, V. S.; Woodard, S. S.; Katsuki, T.; Yamada, Y.; Ikeda, M.; Sharpless, K. B. *J. Am. Chem. Soc.* **1981**, *103*, 6237–6240; (b) Radha Krishna, P.; Kannan, V.; Ilangovan, A.; Sharma, G. V. M. *Tetrahedron: Asymmetry* **2001**, *12*, 829–837.
- (a) Sharpless, K. B. *Janssen Chim. Acta* **1988**, *6*, 3. *Chem. Abstr.* **1988**, *109*, 128034a; (b) Wershofen, S.; Scharf, H.-D. *Synthesis* **1988**, 854–857.
- (a) Garber, B. S.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2000**, *122*, 8168–8179; (b) Gessler, S.; Randi, S.; Blechert, S. *Tetrahedron Lett.* **2000**, *41*, 9973–9976; (c) Wang, H.; Matsubashi, H.; Doan, D. B.; Goodmen, S. N.; Ouyang, X.; Clark, W. M., Jr. *Tetrahedron* **2009**, *65*, 6291–6303; (d) Radha Krishna, P.; Kadiyala, R. R. *Tetrahedron Lett.* **2010**, *51*, 2586–2588.
- Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155–4156.
- Spectral data for selected compounds:** **Compound 5:** colorless syrup.  $[\alpha]_D^{25} -18.0$  (c 0.51, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.17 (s, 1H), 5.78 (s, 1H), 4.57 (q, 1H, J = 6.4, 12.8 Hz), 4.20 (q, 2H, J = 6.9, 7.1 Hz), 1.38–1.31 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 166.8, 143.4, 123.9, 67.6, 61.2, 21.9, 14.1. ESIMS: m/z 167 (M+Na)<sup>+</sup>. IR (neat): 3448, 1622, 1747 cm<sup>-1</sup>. **Compound 12:** colorless syrup.  $[\alpha]_D^{25} -84.0$  (c 0.2, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.15 (d, 2H, J = 10.1 Hz), 4.54 (d, 1H, J = 6.7 Hz), 4.51 (d, 1H, J = 6.7 Hz), 4.21 (q, 1H, J = 6.6, 13.2 Hz), 3.84 (d, 1H, J = 11.2 Hz), 3.68 (d, 1H, J = 13.5 Hz), 3.39 (d, 1H, J = 1.9 Hz), 3.38 (s, 3H), 2.95–2.92 (m, 1H), 1.34 (d, 3H, J = 6.6 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 146.3, 111.7, 94.7, 73.0, 61.8, 61.0, 56.1, 54.7, 21.6. ESIMS: m/z 211 (M+Na)<sup>+</sup>. IR (neat): 3450, 1629 cm<sup>-1</sup>. **Compound 3:** colorless syrup.  $[\alpha]_D^{25} +114.0$  (c 0.3, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.91–5.77 (m, 1H), 5.25 (d, 1H, J = 10.5 Hz), 5.23 (s, 2H), 5.09 (d, 1H, J = 10.5 Hz), 4.61–4.35 (m, 6H), 4.20 (q, 1H, J = 6.6, 12.8 Hz), 3.39 (s, 3H), 3.33 (s, 3H), 1.81–1.75 (m, 2H), 1.29 (d, 3H, J = 6.4 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 149.4, 140.4, 114.2, 96.0, 93.9, 93.4, 75.2, 72.2, 71.6, 55.8, 55.2, 42.8, 20.6. IR (neat): 3345, 1625 cm<sup>-1</sup>. ESIMS: m/z 283 (M+Na)<sup>+</sup>, HRMS m/z: Calcd for C<sub>13</sub>H<sub>24</sub>O<sub>5</sub>Na: 283.1322. Found: 283.1328. **Compound 2:** colorless syrup.  $[\alpha]_D^{25} -46.5$  (c 0.35, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 5.89 (d, 1H, J = 11.7 Hz), 4.73–4.62 (m, 6H), 4.49–4.42 (m, 1H), 3.39 (s, 3H), 3.38 (s, 3H), 1.76–1.67 (m, 2H), 1.31 (d, 3H, J = 6.4 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 131.2, 131.5, 94.6, 95.5, 79.1, 73.9, 69.5, 55.8, 42.2, 21.0. IR (neat): 3552, 1632 cm<sup>-1</sup>. ESIMS: m/z 255 (M+Na)<sup>+</sup>, HRMS m/z: Calcd for C<sub>11</sub>H<sub>20</sub>O<sub>5</sub>Na: 255.1463. Found: 255.1465. **Compound 15:** colorless syrup.  $[\alpha]_D^{25} -133.1$  (c 0.44, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.21 (s, 1H), 4.82 (br d, 1H, J = 6.0 Hz), 4.75–4.64 (m, 5H), 3.42 (s, 3H), 3.40 (s, 3H), 2.77 (dd, 1H, J = 6.0, 12.0 Hz), 2.41 (dd, 1H, J = 2.2, 15.5 Hz), 1.41 (3H, d, J = 6.7 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 204.4, 179.5, 129.8, 96.3, 94.9, 74.1, 69.6, 56.0, 55.4, 43.3, 19.6. IR (neat): 1735, 1620 cm<sup>-1</sup>. ESIMS: m/z 253 (M+Na)<sup>+</sup>, HRMS m/z: Calcd for C<sub>11</sub>H<sub>18</sub>O<sub>5</sub>Na: 253.1139. Found: 253.1134. **Compound 1:** solid. Mp 99–101.  $[\alpha]_D^{25} -27.5$  (c 0.17, CHCl<sub>3</sub>); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 6.09 (s, 1H, H-2), 5.07 (br d, 1H, J = 5.3 Hz, H-4), 4.93 (q, 1H, J = 6.4 Hz, H-6), 2.86 (dd, 1H, J = 6.4, 18.5 Hz, H-5), 2.42 (dd, 1H, J = 1.8, 16.7 Hz, H-5), 1.53 (d, 3H, J = 6.7 Hz, H-7). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 205.5, 181.5, 129.0, 71.2, 67.0, 45.3, 22.5. IR (neat): 3435, 1742, 1621 cm<sup>-1</sup>. ESIMS: m/z 165 (M+Na)<sup>+</sup>, HRMS m/z: Calcd for C<sub>7</sub>H<sub>10</sub>O<sub>3</sub>Na: 165.1266. Found: 165.1269.